Novo Nordisk is introducing Awiqli, a once-weekly insulin injection, in the Indian market for Type 1 and Type 2 diabetes patients. The company aims to simplify treatment by reducing annual injections from 365 to 52. Investors are monitoring how this pricing strategy and clinical profile affect its competitive standing against established basal insulin brands.
Novo Nordisk has announced the launch of Awiqli in India, marking a significant entry for its once-weekly basal insulin therapy. By reducing the frequency of injections to once per week, the company aims to address patient fatigue associated with daily insulin administration. India is among the first countries where this therapy is being introduced, highlighting the company’s strategic focus on the large and growing diabetic population in the region.
Pricing and Market Positioning
The company has set the price at approximately ₹3.5 per unit. Novo Nordisk indicates that the annual cost of treatment with Awiqli is expected to be 20% to 25% lower than current analogue basal insulin therapies. This pricing strategy is designed to compete with established options like insulin degludec and insulin glargine. In India, Awiqli has secured approval for use in both Type 1 and Type 2 diabetes. This is a wider regulatory clearance compared to the United States, where approval is currently restricted to Type 2 diabetes patients.
Clinical Profile and Patient Outcomes
The therapy, known chemically as insulin icodec, is designed to maintain steady blood glucose levels over a full week. Clinical trial data presented by the company suggests that patients experienced improved time in range, which measures the percentage of time glucose levels remain within target limits. However, clinical studies have also indicated a potential for a higher frequency of hypoglycemia—episodes of low blood sugar—among Type 1 diabetes patients when compared to conventional daily insulin treatments. Managing this safety profile will be an important factor for healthcare providers as they integrate this new therapy into patient care plans.
Strategic Importance for Novo Nordisk
For Novo Nordisk, the introduction of Awiqli is a move to defend its market share in the insulin segment. The global diabetes care market is highly competitive, with established players and biosimilar manufacturers constantly working to lower costs or improve delivery mechanisms. By moving toward a once-weekly administration model, Novo Nordisk is attempting to differentiate its offering from standard daily analogues.
Investors may monitor the adoption rate of this product, as its success will depend on how quickly physicians shift prescribing habits and how effectively the company manages the potential safety concerns noted in clinical trials. The next steps for the company include tracking the commercial uptake in urban centers and the feedback from endocrinologists regarding patient adherence and long-term glycemic control.